U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19NO4
Molecular Weight 301.3371
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYMORPHONE

SMILES

CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@]3(O)CCC4=O)=CC=C5O

InChI

InChIKey=UQCNKQCJZOAFTQ-ISWURRPUSA-N
InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H19NO4
Molecular Weight 301.3371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf | https://www.drugs.com/pro/oxymorphone.html

Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.

Originator

Sources: DOI:10.1021/ja01627a033

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

-3.39292815E11
Palliative
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

-3.39292815E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.21 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.54 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.47 ng/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.59 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.27 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.7 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17.81 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
19.28 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
36.98 ng × h/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
37.9 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.54 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.6 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.89 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
9.35 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
11.3 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources: Page: p.97
healthy, 27–44
n = 23
Health Status: healthy
Age Group: 27–44
Sex: M+F
Population Size: 23
Sources: Page: p.97
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (mild, 4.3%)
Nausea (4.3%)
Dizziness (4.3%)
Sources: Page: p.97
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Disc. AE: Abdominal pain, Chest pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.4%)
Chest pain (1.4%)
Serum creatine phosphokinase increased (1.4%)
Serum creatine phosphokinase MB increased (1.4%)
Back pain (1.4%)
Sources: Page: p.26
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources: Page: p.6
1.5 mg 5 times / day multiple, intramuscular|subcutaneous (max)
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources: Page: p.6
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Disc. AE: Opioid abuse, Addiction...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Addiction
Respiratory depression (grade 3-5)
Withdrawal syndrome neonatal
Anaphylaxis
Hypotension (severe)
Angioedema
Hypersensitivity reaction
Adrenal insufficiency
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dizziness 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources: Page: p.97
healthy, 27–44
n = 23
Health Status: healthy
Age Group: 27–44
Sex: M+F
Population Size: 23
Sources: Page: p.97
Nausea 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources: Page: p.97
healthy, 27–44
n = 23
Health Status: healthy
Age Group: 27–44
Sex: M+F
Population Size: 23
Sources: Page: p.97
Vomiting mild, 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources: Page: p.97
healthy, 27–44
n = 23
Health Status: healthy
Age Group: 27–44
Sex: M+F
Population Size: 23
Sources: Page: p.97
Abdominal pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Back pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Chest pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Serum creatine phosphokinase MB increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Serum creatine phosphokinase increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral (mean)
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources: Page: p.26
unhealthy, 45.5-47.5
n = 71
Health Status: unhealthy
Condition: Back pain
Age Group: 45.5-47.5
Sex: M+F
Population Size: 71
Sources: Page: p.26
Addiction Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Opioid abuse Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Respiratory depression Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Hypotension severe
Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Addiction Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous (max)
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Opioid abuse Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous (max)
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Respiratory depression Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous (max)
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Hypotension severe
Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous (max)
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.6
Addiction Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Adrenal insufficiency Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Anaphylaxis Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Angioedema Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Hypersensitivity reaction Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Opioid abuse Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Withdrawal syndrome neonatal Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Respiratory depression grade 3-5
Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Hypotension severe
Disc. AE
20 mg 5 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Antagonism in opioid peptides: the role of conformation.
2004
Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study.
2004 Apr
Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs.
2004 Apr
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
2004 Apr
Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs.
2004 Jan
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
2004 Jun
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
2004 Mar 11
Screening postmortem whole blood for oxycodone by ELISA response ratios.
2004 May
The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain.
2004 Nov
Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.
2005
Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.
2005
Gluten exorphin B5 stimulates prolactin secretion through opioid receptors located outside the blood-brain barrier.
2005 Feb 25
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
2005 Jan
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.
2005 Mar
Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
2005 May 5
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
2005 Sep-Oct
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
2006
Dissociative anaesthesia during field and hospital conditions for castration of colts.
2006
Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.
2006 Apr 4
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization.
2006 Jul
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.
2006 Jun 5
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
2006 Mar
Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory.
2006 Mar
Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites.
2006 Oct
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
2006 Oct
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
2007 Apr 1
GC-MS analysis of multiply derivatized opioids in urine.
2007 Aug
Comment: Oral oxymorphone for pain management.
2007 Dec
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.
2007 Feb
Extended-duration agents for perioperative pain management.
2007 Feb
Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.
2007 Feb
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
2007 Feb
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia.
2007 Feb
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
2007 Jan
New pain management options: drugs.
2007 Jan
Oral oxymorphone (Opana).
2007 Jan 1
The effect of opiates on the activity of human placental aromatase/CYP19.
2007 Jan 15
Oral extended-release oxymorphone: a new choice for chronic pain relief.
2007 Jul
Oral oxymorphone for pain management.
2007 Jul
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
2007 Jul 2
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
2007 Jun
Nociception increases during opioid infusion in opioid receptor triple knock-out mice.
2007 Jun 29
Oxymorphone hydrochloride, a potent opioid analgesic, is not carcinogenic in rats or mice.
2007 Mar
Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis.
2007 Mar 23
Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
2007 Mar 8
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base.
2007 May 30
Determination of opioid analgesics in hair samples using liquid chromatography/tandem mass spectrometry and application to patients under palliative care.
2007 Oct
Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry.
2007 Sep
Rapid analysis of metabolites and drugs of abuse from urine samples by desorption electrospray ionization-mass spectrometry.
2007 Sep
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
2008 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf
Subcutaneous or Intramuscular administration: Initiate treatment with 1mg to 1.5 mg, every 4 to 6 hours. Intravenous Administration: 0.5 mg initially Oral: 10 to 20 mg every four to six hours.
Route of Administration: Other
In Vitro Use Guide
Oxymorphone hydrochloride was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test) at concentrations of ≤5270 ug/plate, or in an in vitro mammalian cell chromosome aberration assay performed with human peripheral blood lymphocytes at concentrations ≤5000 ug/mL with or without metabolic activation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:16:42 UTC 2023
Edited
by admin
on Fri Dec 15 16:16:42 UTC 2023
Record UNII
9VXA968E0C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYMORPHONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
OXYMORPHONE CII [USP-RS]
Common Name English
OXYCODONE HYDROCHLORIDE IMPURITY A [EP IMPURITY]
Common Name English
4,5.ALPHA.-EPOXY-3,14-DIHYDROXY-17-METHYLMORPHINAN-6-ONE
Systematic Name English
NIH 10323
Code English
OXYMORPHONE [VANDF]
Common Name English
OXYCODONE HYDROCHLORIDE IMPURITY, OXYMORPHONE- [USP IMPURITY]
Common Name English
DIHYDROXYMORPHINONE
Common Name English
IDS-NO-003
Code English
MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-
Systematic Name English
14-HYDROXYDIHYDROMORPHINONE
Common Name English
oxymorphone [INN]
Common Name English
OXYMORPHONE CII
USP-RS  
Common Name English
7,8-DIHYDRO-14-HYDROXYMORPHINONE
Common Name English
Oxymorphone [WHO-DD]
Common Name English
OXYMORPHONE [MI]
Common Name English
NSC-19045
Code English
Classification Tree Code System Code
NDF-RT N0000175690
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
LIVERTOX NBK548775
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
NDF-RT N0000175684
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
NCI_THESAURUS C1506
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
FDA ORPHAN DRUG 6185
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
DEA NO. 9652
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
Code System Code Type Description
HSDB
8060
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
RXCUI
7814
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C29314
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
PUBCHEM
5284604
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
NSC
19045
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
EVMPD
SUB09569MIG
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
DAILYMED
9VXA968E0C
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
MERCK INDEX
m8338
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
OXYMORPHONE
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
DRUG BANK
DB01192
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-959-7
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL963
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023409
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
FDA UNII
9VXA968E0C
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
DRUG CENTRAL
2034
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
LACTMED
Oxymorphone
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
SMS_ID
100000083286
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
INN
937
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
MESH
D010111
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
RS_ITEM_NUM
1488000
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
IUPHAR
7094
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
CAS
76-41-5
Created by admin on Fri Dec 15 16:16:42 UTC 2023 , Edited by admin on Fri Dec 15 16:16:42 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
6-OH-oxymorphone has been shown in animal studies to have analgesic bioactivity
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
MAJOR
PLASMA
PARENT -> METABOLITE ACTIVE
Highly variable 40 fold higher potency than Oxycodone
MINOR
PLASMA; URINE
METABOLITE -> PARENT
6-OH-oxymorphone has been shown in animal studies to have analgesic bioactivity.
MAJOR
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC